Diosma Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.00 M
- Revenue Growth 53.78%
- Profit Growth -911.70%
- Ebitda -302.78%
- Net Worth -55.07%
- Total Assets -51.26%
About Diosma Lifesciences
Diosma Lifesciences Private Limited (DLPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 June 2014 and has a history of Ten years and eight months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹9.00 M.
Girish Singh and Priyanka Singh serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24233MH2014PTC255369
- Company No.
255369
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jun 2014
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Diosma Lifesciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Girish Singh  | Director | 04-Jun-2014 | Current |
| Priyanka Singh | Director | 16-Aug-2016 | Current |
Financial Performance of Diosma Lifesciences.
Diosma Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 53.78% increase. The company also saw a substantial fall in profitability, with a 911.7% decrease in profit. The company's net worth observed a substantial decline by a decrease of 55.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Diosma Lifesciences?
In 2022, Diosma Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Open Charges
₹9.00 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Others : 0.90 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Oct 2023 | Others | ₹9.00 M | Open |
How Many Employees Work at Diosma Lifesciences?
Diosma Lifesciences has a workforce of 0 employees as of Mar 26, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Diosma Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Diosma Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
